Physician profile
Matthew A Torrington
NPI 1568581296
$77,393.35
in general payments reported to CMS, 2019-2025
10 companies · $152 in 2025
The $152 reported for 2025 was more than what a typical Addiction Medicine (Family Medicine) provider received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $9,187 · 2021: $21.08 · 2022: $2,904 · 2023: $124 · 2024: $238 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Titan Pharmaceuticals, INC. | $64,951.87 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $4,986.05 | 2020-2022 | |
| Indivior INC. | $2,521.90 | 2020-2025 | Sublocade |
| Orexo US, INC. | $2,347.52 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,176.00 | 2019 | |
| Janssen Biotech, INC. | $152.90 | 2024-2025 | Tremfya |
| Incyte Corporation | $146.14 | 2023-2024 | Opzelura |
| Lilly USA, LLC | $55.37 | 2024 | Taltz, Zepbound, Olumiant |
| Regeneron Healthcare Solutions, INC. | $37.23 | 2024 | Dupixent |
| Abbvie INC. | $18.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Torrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.